Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Govt Panel Members Call for Drastic Drug Pricing Reform, Annual Revision
October 24, 2016
- Keytruda’s November Listing Skip Likely amid Opdivo Re-Pricing Fuss
October 24, 2016
- New Govt Panel Holds 1st Meeting for Healthcare, Long-Term Care
October 21, 2016
- MHLW Panel to Discuss Health Coverage of Ethical Drugs with OTC Versions on Oct. 26
October 21, 2016
- Oct. 27 MHLW Panel Meeting Postponed Due to Lack of Quorum
October 21, 2016
- Basic Policy on JP 18th Edition Calls for Expansion of Sections Related to Biopharmaceuticals: MHLW
October 21, 2016
- Heads of Medicines Regulatory Agencies to Hold Summit in Kyoto Next October
October 20, 2016
- Shiozaki Asks for Early Enactment of Clinical Research Bill
October 20, 2016
- MHLW Task Force Calls for Consolidation in Vaccines, Blood Products Industries; “Fundamental to National Security”: Minister
October 20, 2016
- LDP Taskforce Agrees to Squeeze Social Security Budget by 140 Billion Yen
October 19, 2016
- Opdivo Ordered to Add Immune Thrombocytopenic Purpura in ADR List
October 19, 2016
- Concomitant Use of Warfarin and Florid Contraindicated: MHLW
October 19, 2016
- Health Minister Nudges Kaketsuken on Biz Handover to Astellas
October 19, 2016
- Urgent Need for Rule on Interim NHI Price Revisions; Current System Unable to Respond in Case of Add’l Indications: MOF Budget Examiner
October 19, 2016
- MHLW Panel to Review Ono’s Etelcalcetide on Oct. 31
October 18, 2016
- Govt to Stockpile Qinghai Strain Pre-Pandemic Flu Vaccines
October 18, 2016
- Govt Panel Member Pushes 50%-Plus Cut for Opdivo Price
October 17, 2016
- MHLW Panel to Discuss Opdivo for Hodgkin’s Lymphoma on Oct. 27
October 17, 2016
- Huge Costs, Amount of Application Data Required Will Be Major Challenges in Development of Biosimilars: Open Forum
October 14, 2016
- Health Minister to “Positively Consider” Setting Biosimilars Use Target
October 14, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…